First Indigenous COVID Drug Vincov-19 Completes Trial, Says CSIR

With the completion of clinical trials that demonstrated excellent results, the primary indigenous drug to treat COVID-19 named Vincov-19 is anticipated to be made available to the general public soon.

CSIR-Centre for Cellular & biological science (CCMB), VINS Bioproducts and the University of Hyderabad (UoH) has collaborated to make the drug, Vincov-19.

To create this drug, the foremost step taken was the SARS-CoV-2 virus was inactivated and injected into horses. Then the anti-bodies that are generated through the bodily fluid are synthesized to purify and produce a drug. This drug is later on injected into humans to neutralise the COVID virus.

Hyderabad firm gets nod for Covid antidote VINCOV-19 trials | Hyderabad News - Times of IndiaThe CCMB is an Indian fundamental bioscience research institute based in Hyderabad. UNESCO’s Global Molecular and Cell Biology Network have designated CCMB as a “Centre of Excellence.” It is a number one research institute that conducts high-quality basic research and training in areas of recent biology, in addition to promoting centralised national facilities for new techniques in interdisciplinary fields of biology. It was established as a semi-autonomous centre on April 1, 1977.

Researchers tackle the surface transmission of COVID-19 in new partnershipThe pandemic has demonstrated that the country must become self-sufficient in terms of healthcare, instead of relying only on imports. CCMB and other scientific institutes rose to the challenge in a very short period of your time, developing diagnostic kits, testing facilities, gadgets, genomics, and deals on over 170 possible regents and medicines.